Tag: MONOGRAPH

  • Bryostatin-1

    Macrocyclic lactone protein kinase C modulator with sub-nanomolar affinity for the C1 regulatory domain

    A marine-derived macrolide isolated from the bryozoan Bugula neritina, distinguished from classical phorbol ester PKC activators by isoform-selective modulation producing anti-inflammatory, synaptogenic, and latent HIV-reversing activity at sub-nanomolar concentrations without tumor-promoting effects.

    Abstract

    Bryostatin-1, the prototypical member of the bryostatin family of macrocyclic lactones, is a highly oxygenated 26-membered macrolide originally isolated from the marine bryozoan Bugula neritina and subsequently attributed to the bacterial endosymbiont Candidatus Endobugula sertula. The compound binds the C1 regulatory domain of protein kinase C (PKC) at the conserved diacylglycerol (DAG) binding site with sub-nanomolar affinity, modulating both conventional (alpha, betaI/betaII, gamma) and novel (delta, epsilon, eta, theta) PKC isoforms. Despite competitive displacement of phorbol esters from the C1 domain, bryostatin-1 produces functionally distinct downstream signaling characterized by initial PKC activation followed by isoform-selective downregulation, a pharmacological profile that distinguishes it from tumor-promoting phorbol esters and underwrites its diverse therapeutic applications across oncology, neurology, immunology, and infectious disease.

    The compound entered clinical development through the National Cancer Institute (NCI) in the early 1990s as an antineoplastic agent, advancing through more than 80 Phase 1 and Phase 2 oncology trials enrolling over 1,500 patients across multiple solid tumor and hematological malignancy indications. Single-agent antitumor activity was modest, though combination regimens with cytarabine in acute myeloid leukemia and with vincristine in non-Hodgkin lymphoma produced response rates warranting further investigation. The oncology program did not yield a registration-quality efficacy signal, and active NCI-sponsored oncology development was substantially curtailed by 2010.

    A second clinical trajectory, initiated by Alkon and colleagues at the Blanchette Rockefeller Neurosciences Institute and subsequently advanced by Synaptogenix (formerly Neurotrope), repositioned bryostatin-1 as a cognitive enhancement agent for Alzheimer’s disease on the basis of PKC epsilon activation, synaptogenesis induction, and amyloid precursor protein alpha-secretase processing. A Phase 2a trial (Nelson et al. 2017) demonstrated safety at 25 micrograms per square meter and produced signals of PKC epsilon activation and cognitive stabilization. A larger NIH-sponsored Phase 2 trial (NCT04538066) in 122 patients with moderately severe Alzheimer’s disease reported that the primary endpoint (change from baseline in Severe Impairment Battery score at week 28) was not met with statistical significance across the full analysis population. However, prespecified secondary analysis of the severe cohort (Mini-Mental State Examination 10 to 14) demonstrated that bryostatin-treated patients showed no significant cognitive decline over 10 months, compared with placebo patients who declined by 12.8 Severe Impairment Battery points, a finding published in the Journal of Alzheimer’s Disease in 2023. The compound was well tolerated in the Alzheimer’s trials with no drug-related serious adverse events and no cases of the myalgia observed at higher oncology doses.

    A third research application addresses HIV latency reversal. Bryostatin-1 reactivates latent HIV-1 provirus through PKC-mediated NF-kappaB activation in both lymphocytic and monocytic cellular reservoirs, including astrocytes, at low nanomolar concentrations. The Wender laboratory at Stanford developed a scalable 29-step total synthesis (2017) and characterized synthetic bryostatin analogs (bryologs) as latency-reversing agents with an expanded therapeutic window, establishing the foundation for a “kick and kill” eradication strategy in combination with antiretroviral therapy.

    Pharmacokinetics following intravenous administration are characterized by a two-compartment disposition model with distribution and elimination half-lives of approximately 1 and 23 hours, respectively. The compound distributes widely to lung, liver, gastrointestinal tract, and adipose tissue, with evidence of enterohepatic circulation. Renal excretion accounts for approximately 23 percent of the administered dose in the first 12 hours; fecal excretion accounts for approximately 40 percent by 72 hours. The compound is not orally bioavailable at therapeutically relevant concentrations and is administered exclusively by intravenous infusion in clinical applications.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Hopantenic acid

    Pantoyl-GABA conjugate nootropic with GABAergic, cholinergic, and pantothenic acid-related central nervous system activity

    A synthetic homolog of pantothenic acid in which beta-alanine is replaced by gamma-aminobutyric acid, developed in the Soviet Union and Japan as a nootropic and neuroprotective agent with registered indications across pediatric and adult neurology in the Russian Federation.

    Abstract

    Hopantenic acid (homopantothenic acid, D-homopantothenic acid, N-pantoyl-GABA) is a synthetic structural analog of pantothenic acid (vitamin B5) in which the beta-alanine moiety is replaced by gamma-aminobutyric acid (GABA), producing a hybrid molecule that combines GABAergic pharmacology with pantothenate-related metabolic activity and the capacity to cross the blood-brain barrier, a property that free GABA lacks. The compound was first synthesized in the 1950s in Japan, entered clinical use as the calcium salt (calcium hopantenate) in Japan in 1978 and in the Soviet Union in 1977, and is registered in the Russian Federation under the brand names Pantogam and Pantocalcin for a broad range of neurological, psychiatric, and developmental indications in children and adults, including cognitive impairment of cerebrovascular origin, attention deficit hyperactivity disorder, perinatal encephalopathy, cerebral palsy with hyperkinetic features, epilepsy adjunctive therapy, neurogenic bladder disorders, stuttering, and tic disorders. A racemic formulation (D,L-hopantenic acid, marketed as Pantogam Active) was introduced in Russia in 2008 and exhibits enhanced anxiolytic and anticonvulsant properties attributed to the L-isomer’s interaction with GABA-A receptors and dopamine D2 receptors. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by any Western regulatory authority. The molecular pharmacology of hopantenic acid is multifaceted. At the neurotransmitter level, the compound acts as a weak agonist at the GABA-B receptor complex, with a cross-reactive potency of approximately 0.2 percent relative to GABA in radioreceptor assays, and interacts with GABA-A receptors and dopamine D2 receptors at higher concentrations. In parallel, hopantenic acid enhances high-affinity choline transport into cortical and hippocampal synaptosomes and stimulates choline acetyltransferase activity, producing a secondary cholinergic facilitation that is the principal basis for the nootropic and antidementia pharmacology characterized in preclinical studies by Nakahiro et al. (1988) and others [1, 2]. At the metabolic level, the compound is a competitive antagonist of pantothenic acid at the pantothenate kinase step of coenzyme A (CoA) biosynthesis; phosphorylation by pantothenate kinase produces phospho-hopantenic acid, which potently inhibits phosphopantothenoylcysteine synthetase and reduces cellular CoA levels [3]. This pantothenic acid antagonism is the molecular basis for the most serious reported adverse effect of the compound: a Reye-like syndrome of acute encephalopathy with hepatic steatosis, hyperammonemia, and hypoglycemia reported in multiple case series in Japan during the 1980s, principally in elderly and pediatric patients on chronic high-dose therapy, and reproduced in dogs by Noda et al. (1991) [4, 5, 6]. The encephalopathy was preventable by concurrent pantothenic acid supplementation, confirming the antagonistic mechanism. Pharmacokinetics following oral administration of the calcium salt are characterized by rapid absorption (time to peak plasma concentration approximately 1.5 hours), moderate oral bioavailability (approximately 64 percent in preclinical models), an elimination half-life of approximately 6.7 hours, and predominantly renal excretion without significant hepatic metabolism [7]. The clinical evidence base for hopantenic acid is dominated by Russian-language publications of variable methodological rigor, with the most robust trial being a multicenter, double-blind, placebo-controlled study of Pantogam in 100 children with attention deficit hyperactivity disorder, which reported statistically significant improvement on the ADHD-DSM-IV rating scale and sustained attention measures over four months at 30 mg/kg/day [8]. Additional clinical evidence supports the use of the racemic formulation (Pantogam Active) for cognitive and anxiety disorders in patients with arterial hypertension and chronic cerebral ischemia [9, 10]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SBT-272

    Mitochondria-targeted cardiolipin-stabilizing peptidomimetic with enhanced central nervous system penetration

    A next-generation cardiolipin-binding peptidomimetic developed by Stealth BioTherapeutics as a brain-penetrant successor to elamipretide (SS-31), designed to restore mitochondrial structure and function in neurodegenerative disease with demonstrated preclinical neuroprotection in models of amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, Huntington’s disease, and ischemic stroke.

    Abstract

    SBT-272, also designated bevemipretide (International Nonproprietary Name), is a clinical-stage mitochondria-targeted peptidomimetic small molecule developed by Stealth BioTherapeutics as a structurally optimized successor to elamipretide (SS-31, MTP-131, Bendavia). The compound selectively binds cardiolipin, a diphosphatidylglycerol lipid exclusively localized to the inner mitochondrial membrane, where it stabilizes the organization of electron transport chain complexes into supercomplexes (respirasomes), promotes efficient oxidative phosphorylation, reduces mitochondrial reactive oxygen species generation, and prevents the cytochrome c/cardiolipin peroxidase activity that initiates apoptotic signaling. Relative to the first-generation elamipretide scaffold, SBT-272 demonstrates higher mitochondrial uptake, greater brain accumulation following subcutaneous administration, and improved systemic bioavailability in preclinical species, properties that position the compound for neurodegenerative disease indications where central nervous system exposure is a critical determinant of therapeutic effect.

    The preclinical pharmacology of SBT-272 encompasses multiple neurodegenerative disease models. In TDP-43 mutant upper motor neuron cultures derived from the prpTDP-43(A315T) transgenic mouse, SBT-272 restored mitochondrial structural integrity, recovered mitochondrial motility in a dose-dependent manner, and improved axon outgrowth, a functional indicator of neuronal health, with effects superior to those of edaravone and AMX0035 in the same system [1]. Chronic in vivo treatment for sixty days in the same model significantly reduced astrogliosis, microgliosis, and TDP-43 pathology in the motor cortex [1]. In an alpha-synucleinopathy mouse model of Parkinson’s disease, daily subcutaneous SBT-272 attenuated dopaminergic neuron loss, reduced pathological alpha-synuclein burden, and suppressed neuroinflammatory markers [3]. Additional preclinical neuroprotective activity has been reported in models of frontotemporal lobar dementia, Huntington’s disease, and ischemic stroke [4].

    Interim results demonstrated a pharmacokinetic profile consistent with preclinical allometric scaling predictions, plasma and projected brain exposures at doses anticipated to reach therapeutic concentrations based on preclinical efficacy thresholds, and a safety profile in which the most commonly reported adverse event was mild-to-moderate injection site reaction resolving within approximately 4 hours of dosing [5]. The United States Food and Drug Administration granted Orphan Drug Designation for SBT-272 for the treatment of amyotrophic lateral sclerosis in 2022 [4]. A separate development program for topical ocular bevemipretide (eye drops) in dry age-related macular degeneration has advanced through preclinical studies demonstrating approximately 4- to 6-fold higher retinal tissue concentrations compared to elamipretide, with a 13-week GLP toxicology study informing Phase 1 trial design [6, 7].

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Canagliflozin

    Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with secondary SGLT1 inhibitory activity

    A thiophene-containing C-glucoside developed by Mitsubishi Tanabe Pharma and licensed to Janssen as the first SGLT2 inhibitor approved in the United States, distinguished by dual SGLT2/SGLT1 inhibition and landmark cardiovascular and renal outcomes evidence from the CANVAS Program and CREDENCE trial.

    Abstract

    Canagliflozin is a potent, orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2) and the first agent of its class to receive United States Food and Drug Administration approval for the treatment of type 2 diabetes mellitus. The compound acts through an insulin-independent mechanism by blocking the reabsorption of filtered glucose in the proximal tubule of the kidney, producing sustained glycosuria, reduction in plasma glucose, modest body weight loss, and reduction in systolic blood pressure. Structurally, canagliflozin is a C-glucoside bearing a thiophene ring in the aglycone region, conferring metabolic stability against glucosidase cleavage and contributing to oral bioavailability of approximately 65 percent.

    The compound was discovered at Mitsubishi Tanabe Pharma through systematic optimization of C-glucoside scaffolds for SGLT2 potency, metabolic stability, and oral pharmacokinetics [1]. Janssen Pharmaceuticals obtained development and commercialization rights through a licensing agreement and advanced canagliflozin through a comprehensive Phase 3 program (nine controlled studies, approximately 10,285 subjects) culminating in FDA approval on 29 March 2013 under the trade name Invokana [3, 4]. The compound was subsequently approved by the European Medicines Agency in November 2013 and in multiple additional jurisdictions. A fixed-dose combination with metformin (Invokamet) was approved in 2014.

    The clinical evidence base for canagliflozin extends substantially beyond glycemic control. The CANVAS Program (Canagliflozin Cardiovascular Assessment Study and CANVAS-R; N = 10,142; mean follow-up 188.2 weeks), published by Neal et al. in the New England Journal of Medicine in 2017, demonstrated a statistically significant 14 percent reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.86; 95 percent confidence interval 0.75 to 0.97) [5]. The CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; N = 4,401; median follow-up 2.62 years), published by Perkovic et al. in the New England Journal of Medicine in 2019, demonstrated a 30 percent reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (hazard ratio 0.70; 95 percent confidence interval 0.59 to 0.82), establishing canagliflozin as the first SGLT2 inhibitor with a dedicated positive renal outcomes trial [6].

    The terminal elimination half-life is approximately 10.6 to 13.1 hours at steady state, supporting once-daily dosing. Approximately 60 percent of the administered dose is recovered in feces and 33 percent in urine. Clinically significant drug-drug interactions are limited; UGT enzyme inducers (rifampin, phenytoin, ritonavir) reduce canagliflozin exposure and may require dose adjustment.

    The safety profile includes class-related adverse events: genital mycotic infections (principally vulvovaginal candidiasis in women and balanitis in men; occurring in approximately 10 to 12 percent of patients), urinary tract infections, volume depletion events related to osmotic diuresis, and euglycemic diabetic ketoacidosis (rare but clinically significant). The CANVAS Program identified a signal for increased lower-extremity amputations (6.3 versus 3.4 per 1,000 patient-years; hazard ratio 1.97), predominantly at the toe and metatarsal level, prompting an FDA boxed warning in 2017 that was subsequently removed in 2020 after additional data, including the CREDENCE trial, did not confirm the excess risk at a comparable magnitude [5, 8]. Bone fracture risk was identified in CANVAS but not confirmed in CREDENCE. Fournier gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 inhibitor class.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Hydroxynorketamine

    Cyclohexanone-based ketamine metabolite with AMPA receptor-potentiating and rapid antidepressant activity

    A hydroxylated norketamine metabolite identified as a principal mediator of ketamine’s rapid antidepressant effects, distinguished from the parent compound by the absence of NMDA receptor blockade at therapeutic concentrations, lack of dissociative and abuse-related properties, and a novel mechanism converging on AMPA receptor potentiation, BDNF-TrkB signaling, and mGlu2 receptor-dependent glutamatergic plasticity.

    Abstract

    Hydroxynorketamine (HNK) refers to a family of twelve stereoisomeric metabolites of the dissociative anesthetic and rapid-acting antidepressant ketamine, formed by cytochrome P450-mediated hydroxylation of the intermediate metabolite norketamine at the 4-, 5-, or 6-position of the cyclohexane ring. The (2R,6R)-hydroxynorketamine stereoisomer ((2R,6R)-HNK) has emerged as the compound of greatest pharmacological interest following the seminal 2016 report by Zanos et al. in Nature demonstrating that this metabolite is both necessary and sufficient for the antidepressant actions of ketamine in rodent models, while lacking the anesthetic, dissociative, psychotomimetic, and abuse-related properties of the parent compound. The molecular pharmacology of (2R,6R)-HNK is distinct from ketamine: at concentrations relevant to antidepressant activity, (2R,6R)-HNK does not produce meaningful inhibition of N-methyl-D-aspartate (NMDA) receptors, but instead potentiates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated glutamatergic transmission through a presynaptic mechanism that increases glutamate release probability and enhances synaptic plasticity in hippocampal and prefrontal cortical circuits. Downstream consequences include activity-dependent release of brain-derived neurotrophic factor (BDNF), activation of tropomyosin receptor kinase B (TrkB) signaling, stimulation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway, and rapid synaptogenesis in the medial prefrontal cortex. Additional mechanistic contributions involve metabotropic glutamate receptor subtype 2 (mGlu2) receptor-dependent signaling and antagonism of alpha-7 nicotinic acetylcholine receptors controlling presynaptic function and neuroplasticity gene expression. Pharmacokinetically, (2R,6R)-HNK is formed in vivo from (R)-ketamine through sequential N-demethylation (predominantly CYP2B6 and CYP3A4) to (R)-norketamine and subsequent 6-hydroxylation (predominantly CYP2B6 and CYP2A6). The metabolite is brain-penetrant following peripheral administration, with rapid onset of central nervous system exposure. Phase 2 trials in treatment-resistant depression (NCT06511908) and Phase 1/2 trials in neuropathic pain (NCT05864053) and obsessive-compulsive disorder (NCT06575075) are currently enrolling. Preclinical evidence across multiple rodent models demonstrates antidepressant-like, anxiolytic, analgesic, and anti-inflammatory effects, with effect sizes comparable to or exceeding those of the parent ketamine in several paradigms and duration of action extending well beyond the plasma residence time, consistent with a synaptic plasticity-dependent rather than receptor occupancy-dependent mechanism. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Schisandrin B

    Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

    A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-kB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

    Abstract

    Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of Schisandra chinensis (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the Schisandra fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF-kB nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) through inhibition of IkB-alpha degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid metabolism. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with Schisandra chinensis fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Citrus-Bergamot

    Polyphenol-rich Citrus flavonoid extract with AMPK-activating, hypolipidemic, and insulin-sensitizing activity

    A standardized polyphenolic extract derived from Citrus bergamia Risso & Poiteau, distinguished by the presence of the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanones brutieridin and melitidin, and investigated for cardiovascular risk factor modification through pleiotropic lipid-lowering, glycemic, hepatoprotective, and anti-inflammatory mechanisms.

    Abstract

    Citrus bergamot extract, derived from the juice and albedo of the bergamot orange (Citrus bergamia Risso & Poiteau), is a polyphenol-rich botanical preparation whose pharmacological interest centers on a distinctive flavonoid profile that includes the 3-hydroxy-3-methylglutaryl (HMG)-conjugated flavanone glycosides brutieridin and melitidin, alongside high concentrations of neoeriocitrin, naringin, and neohesperidin. These HMG-bearing flavanones are structurally analogous to the HMG-CoA substrate of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis and the molecular target of statin drugs. In vitro mechanistic studies in HepG2 and Caco-2 cell lines have demonstrated that bergamot polyphenolic fraction (BPF) and its principal constituents reduce HMGCR protein levels, activate AMP-activated protein kinase (AMPK) phosphorylation, stimulate fatty acid oxidation, and inhibit intestinal cholesterol absorption through downregulation of the Niemann-Pick C1-Like 1 (NPC1L1) transporter. The mechanism is therefore distinct from direct competitive HMGCR inhibition by statins and involves transcriptional and post-translational regulation of cholesterol biosynthetic and absorptive pathways.

    Clinical investigation of bergamot polyphenolic extracts has been conducted primarily in Southern Italian populations with hyperlipidemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). A 2020 randomized trial of a bergamot-cardoon combination (Bergacyn) in NAFLD patients over 50 years demonstrated significant reductions in liver steatosis, body weight, and hepatic transaminases.

    The pharmacokinetic profile of bergamot flavonoids in humans is incompletely characterized. Oral consumption produces circulating phase II conjugated metabolites (sulfates and glucuronides of naringenin, hesperetin, and eriodictyol) detectable at 1 and 4 hours post-ingestion, consistent with intestinal deglycosylation and hepatic phase II conjugation. The characteristic HMG-conjugated flavanones brutieridin and melitidin have not been detected in plasma or urine in published pharmacokinetic studies, raising the possibility that their hypolipidemic activity is mediated locally in the gastrointestinal epithelium or through metabolites not yet characterized. The extract is generally well tolerated in clinical studies of up to 24 weeks duration, with adverse events limited to mild gastrointestinal discomfort in a minority of subjects. Bergamot contains furanocoumarins (bergamottin, bergapten) that inhibit CYP3A4, producing clinically relevant interactions with statins metabolized by this isoform (atorvastatin, simvastatin, lovastatin) and other CYP3A4 substrates. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ibogainalog

    Non-selective serotonin receptor modulator, psychoplastogen, and ibogaine-derived tricyclic azepinoindole analog

    A simplified tricyclic ibogaine analog and potent 5-HT2A receptor agonist with psychoplastogenic, antidepressant, and analgesic activity, distinguished from the parent iboga alkaloids by dramatically reduced cardiotoxicity, absence of opioid receptor engagement, and retained promotion of structural neural plasticity.

    Abstract

    Ibogainalog (IBG; 9-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole; CAS 802581-10-8) is a synthetic tricyclic azepinoindole and a structurally simplified analog of the iboga alkaloid ibogaine, first described in the chemical literature by Hester and colleagues in the late 1960s and subsequently characterized in pharmacological detail by the Olson laboratory at the University of California, Davis, beginning in 2020. The compound belongs to the ibogalog structural class, a family of substituted hexahydroazepino[4,5-b]indoles that retain the fused indole-azepine core of the iboga alkaloids while eliminating the isoquinuclidine ring system, yielding a dramatically simplified molecular architecture that is amenable to practical gram-scale synthesis. Ibogainalog is a non-selective serotonin receptor modulator with potent agonist activity at the 5-HT2A receptor (Ki approximately 670 nM; functional EC50 18 to 85 nM, 55 to 93 percent efficacy), the 5-HT6 receptor (EC50 7.1 to 8.8 nM, 83 to 99 percent efficacy), the 5-HT1F receptor (EC50 35 nM, 85 percent efficacy), and the 5-HT1B receptor (EC50 170 nM, 76 percent efficacy), with additional inverse agonist activity at the 5-HT7 receptor (EC50 335 nM) and mixed agonist-antagonist activity at the 5-HT2B and 5-HT2C receptors. The compound is a moderate serotonin reuptake inhibitor (SERT IC50 approximately 400 nM) with selectivity over the norepinephrine and dopamine transporters, and a noncompetitive inhibitor of the alpha-7 nicotinic acetylcholine receptor (IC50 approximately 11.4 micromolar) and a competitive inhibitor of the alpha-9-alpha-10 nicotinic acetylcholine receptor (IC50 approximately 2.9 micromolar). Critically, ibogainalog exhibits dramatically reduced potency at the hERG potassium channel relative to ibogaine (approximately 10-fold reduction), conferring a substantially improved cardiac safety profile; this is a principal design objective of the ibogalog class, given that ibogaine-associated QT prolongation and fatal cardiac arrhythmias have been a central safety concern limiting the clinical translation of ibogaine itself. The compound shows no agonist activity at opioid receptors, distinguishing it from the active ibogaine metabolite noribogaine. In preclinical behavioral models, ibogainalog at 10 mg/kg produces sustained antidepressant-like activity (persisting 72 hours in naive mice and 48 hours in chronically stressed mice) through a volinanserin-sensitive, 5-HT2A receptor-dependent serotonergic mechanism. The compound also produces dose-dependent antinociceptive activity in chronic constriction injury models of neuropathic pain and in dextran sulfate sodium-induced colitis models of visceral pain, with the longest anti-hyperalgesic duration among tested ibogalogs at comparatively lower doses. Analgesic activity is abolished by the 5-HT2A receptor antagonist ketanserin and involves synergistic crosstalk between 5-HT2A and metabotropic glutamate type 2 (mGlu2) receptors. As a psychoplastogen, ibogainalog promotes dendritic arborization and spinogenesis in cortical neurons at levels comparable to ibogaine, an activity mediated through 5-HT2A receptor signaling. Unlike the closely related ibogalog tabernanthalog, ibogainalog produces a measurable head-twitch response in rodent models, suggesting that it may retain psychedelic activity in humans, though the response magnitude is substantially reduced relative to classical psychedelics such as 5-methoxy-N,N-dimethyltryptamine. The compound is not in clinical development as of the date of this monograph; all evidence is preclinical. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Setipiprant

    Selective CRTH2 (prostaglandin D2 receptor 2/DP2) antagonist of the tetrahydropyridoindole structural class

    A potent, orally bioavailable tetrahydropyridoindole antagonist of the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2/DP2), developed at Actelion as an anti-inflammatory candidate for allergic asthma and seasonal allergic rhinitis and subsequently repositioned by Kythera Biopharmaceuticals for androgenetic alopecia on the basis of the Garza et al. (2012) demonstration that prostaglandin D2 is elevated in the bald scalp of men with male pattern hair loss.

    Abstract

    Setipiprant (ACT-129968, KYTH-105) is a tetrahydropyridoindole derivative that acts as a potent, selective, and orally bioavailable antagonist of the chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2), also designated as the prostaglandin D2 receptor 2 (DP2 or GPR44). The compound binds the human CRTH2 receptor with an IC50 of approximately 6 nanomolar and demonstrates approximately 215-fold selectivity over the prostaglandin D2 receptor 1 (DP1), with no meaningful antagonism of the thromboxane receptor or inhibition of cyclooxygenase-1. CRTH2 is a G-protein-coupled receptor expressed on eosinophils, basophils, type 2 innate lymphoid cells, and T-helper 2 lymphocytes; activation by prostaglandin D2 drives chemotaxis, degranulation, and cytokine release from these cells, positioning CRTH2 antagonism as a mechanistically distinct anti-inflammatory strategy in allergic and type 2 inflammatory disease.

    Setipiprant was discovered at Actelion Pharmaceuticals through a lead optimization program focused on improving potency and oral bioavailability within a pyrido[4,3-b]indole scaffold series. The compound advanced through Phase 1 single- and multiple-ascending-dose studies demonstrating favorable tolerability, rapid oral absorption (time to peak concentration approximately 2 to 4 hours), a terminal elimination half-life of 10 to 18 hours, and near-complete recovery of administered radioactivity in a human mass balance study (approximately 88 percent fecal, 12 percent urinary). Approximately 54 percent of administered dose was recovered as unchanged parent compound, indicating that direct fecal excretion rather than hepatic metabolism is the dominant clearance pathway. The two principal circulating metabolites, M7 and M9, are dihydroxy-dihydronaphthalene isomers formed through epoxidation of the naphthyl ring, and neither exceeds 10 percent of parent drug plasma concentrations at steady state.

    Actelion advanced setipiprant through Phase 2 and Phase 3 clinical programs in seasonal allergic rhinitis and a Phase 2a proof-of-mechanism study in allergic asthma. However, the Phase 3 confirmatory trial (n=630) at the same dose failed to replicate the Phase 2 efficacy signal on the primary endpoint (p=0.652), despite adequate methodology and a consistent cetirizine active-reference effect. Actelion discontinued development in the allergic rhinitis and asthma indications and redirected anti-inflammatory efforts to a follow-up CRTH2 antagonist.

    The compound was subsequently repositioned for androgenetic alopecia following the Garza et al. (2012) demonstration in Science Translational Medicine that prostaglandin D2 synthase and prostaglandin D2 are elevated in the bald scalp of men with androgenetic alopecia and that prostaglandin D2 inhibits hair follicle growth through the CRTH2/GPR44 receptor. Kythera Biopharmaceuticals acquired the rights to setipiprant and submitted an Investigational New Drug application to the FDA in September 2015 (designated KYTH-105). The trial did not meet either coprimary endpoint: target area hair count change was 6.7 hairs per square centimeter with setipiprant versus 7.0 with placebo (p=0.92), and subject self-assessment showed no difference (p=0.91). Setipiprant was well tolerated throughout all clinical programs, with headache as the most frequently reported adverse event and no severe or clinically significant safety signals identified across more than 1,500 subjects exposed in clinical trials.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cogitum

    Acetylated amino acid derivative; synthetic N-acetylaspartate analog with neurometabolic and adaptogenic activity

    A potassium salt of N-acetyl-DL-aminosuccinic acid developed in France as an oral neurometabolic tonic for asthenic syndrome, cognitive fatigue, and pediatric neurodevelopmental delay, distinguished by its structural relationship to endogenous N-acetylaspartate and downstream modulation of glutamatergic and myelinogenic pathways.

    Abstract

    Cogitum is the proprietary pharmaceutical preparation of potassium N-acetyl-DL-aminosuccinate (bipotassium acetylaminosuccinate), a synthetic analog of N-acetylaspartate (NAA), the most concentrated free amino acid derivative in the mammalian central nervous system. The compound was developed in France and patented in the United States in 1969 (US 3,433,875) for the improvement of mental performance in adults experiencing intellectual overwork, memory disorders, and cognitive decline associated with senescence. The active substance provides an exogenous source of the acetylated aspartate moiety that participates in neuronal energy metabolism through the tricarboxylic acid cycle, serves as the obligate precursor for myelin lipid synthesis via oligodendrocytic aspartoacylase-mediated deacetylation, functions as an osmolyte maintaining neuronal volume homeostasis, and is the direct biosynthetic precursor of N-acetylaspartylglutamate (NAAG), the most abundant neuropeptide in the human brain and an endogenous agonist at the presynaptic metabotropic glutamate receptor type 3 (mGluR3).

    Pediatric evidence comprises a 249-patient study in children with ADHD and subclinical epileptiform electroencephalographic activity demonstrating significant improvements in attention, memory, and speech without aggravation of epileptiform discharges or provocation of seizures; additional cohort studies in children with speech delay, traumatic brain injury sequelae, mental retardation, and schizotypal spectrum disorders have reported efficacy in improving cognitive and linguistic performance. The pharmacological rationale rests on the established neurobiology of endogenous N-acetylaspartate: NAA concentrations in the brain reach 10 millimolar or greater, are confined almost exclusively to neurons, and serve as the principal magnetic resonance spectroscopy marker of neuronal viability; reduced NAA is a consistent finding in neurodegenerative disease, traumatic brain injury, multiple sclerosis, and neurodevelopmental disorders. The exogenous provision of the acetylaminosuccinate moiety is hypothesized to support neuronal mitochondrial energy production, to provide acetate substrate for oligodendrocytic myelin lipid synthesis, and to augment NAAG-mediated glutamatergic neuromodulation.

    Safety data across pediatric and adult populations demonstrate excellent tolerability. The compound has no reported cases of overdose toxicity, produces no clinically significant drug interactions at registered doses, and is contraindicated only in cases of known hypersensitivity to the active substance or excipients. The principal limitation of the evidence base is the concentration of clinical research in Russian-language journals with limited replication in Western multicenter trial frameworks. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.